Nifty
Sensex
:
:
18338.55
61305.95
176.80 (0.97%)
568.90 (0.94%)

Pharmaceuticals & Drugs - Global

Rating :
32/99

BSE: 524816 | NSE: NATCOPHARM

889.85
14-Oct-2021
  • Open
  • High
  • Low
  • Previous Close
  •  898.00
  •  902.80
  •  888.20
  •  894.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  178724
  •  1601.87
  •  1189.00
  •  771.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 16,249.95
  • 41.34
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 16,234.05
  • 0.59%
  • 3.89

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 48.87%
  • 2.94%
  • 16.56%
  • FII
  • DII
  • Others
  • 12.53%
  • 16.78%
  • 2.32%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.63
  • 0.31
  • -0.68

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.68
  • -2.37
  • -5.27

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 22.15
  • -1.93
  • -11.88

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 32.93
  • 26.20
  • 22.86

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.47
  • 4.98
  • 3.54

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.42
  • 19.28
  • 17.35

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Net Sales
410.30
563.40
-27.17%
331.30
454.80
-27.15%
355.20
482.20
-26.34%
802.20
485.70
65.16%
Expenses
300.50
392.30
-23.40%
255.10
326.50
-21.87%
272.70
353.50
-22.86%
525.80
351.40
49.63%
EBITDA
109.80
171.10
-35.83%
76.20
128.30
-40.61%
82.50
128.70
-35.90%
276.40
134.30
105.81%
EBIDTM
26.76%
30.37%
23.00%
28.21%
23.23%
26.69%
34.46%
27.65%
Other Income
17.00
18.70
-9.09%
28.40
22.40
26.79%
30.80
30.80
0.00%
25.70
33.20
-22.59%
Interest
2.00
3.70
-45.95%
3.50
3.50
0.00%
3.40
5.30
-35.85%
2.70
6.20
-56.45%
Depreciation
33.80
28.00
20.71%
30.40
30.50
-0.33%
29.80
25.40
17.32%
28.70
21.90
31.05%
PBT
91.00
158.10
-42.44%
70.70
116.70
-39.42%
80.10
128.80
-37.81%
270.70
139.40
94.19%
Tax
16.00
36.00
-55.56%
17.70
23.50
-24.68%
16.70
24.40
-31.56%
66.80
21.70
207.83%
PAT
75.00
122.10
-38.57%
53.00
93.20
-43.13%
63.40
104.40
-39.27%
203.90
117.70
73.24%
PATM
18.28%
21.67%
16.00%
20.49%
17.85%
21.65%
25.42%
24.23%
EPS
4.11
6.75
-39.11%
2.90
5.17
-43.91%
3.45
5.74
-39.90%
11.12
6.54
70.03%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
1,899.00
2,052.10
1,915.00
2,094.50
2,184.80
2,020.20
1,141.30
825.28
738.89
660.53
523.72
Net Sales Growth
-4.39%
7.16%
-8.57%
-4.13%
8.15%
77.01%
38.29%
11.69%
11.86%
26.12%
 
Cost Of Goods Sold
411.60
483.70
354.40
332.70
411.10
599.10
341.10
242.37
233.23
242.80
203.08
Gross Profit
1,487.40
1,568.40
1,560.60
1,761.80
1,773.70
1,421.10
800.20
582.90
505.67
417.73
320.64
GP Margin
78.33%
76.43%
81.49%
84.12%
81.18%
70.34%
70.11%
70.63%
68.44%
63.24%
61.22%
Total Expenditure
1,354.10
1,445.90
1,332.40
1,299.70
1,256.40
1,336.80
868.70
611.90
559.56
510.60
414.38
Power & Fuel Cost
-
61.10
62.40
59.60
56.20
50.50
43.70
43.24
44.77
38.75
26.88
% Of Sales
-
2.98%
3.26%
2.85%
2.57%
2.50%
3.83%
5.24%
6.06%
5.87%
5.13%
Employee Cost
-
414.90
375.00
355.90
325.60
243.20
189.60
136.92
112.77
102.29
80.05
% Of Sales
-
20.22%
19.58%
16.99%
14.90%
12.04%
16.61%
16.59%
15.26%
15.49%
15.28%
Manufacturing Exp.
-
291.90
243.30
276.40
182.60
141.20
105.20
73.04
76.57
65.10
43.32
% Of Sales
-
14.22%
12.70%
13.20%
8.36%
6.99%
9.22%
8.85%
10.36%
9.86%
8.27%
General & Admin Exp.
-
116.70
132.60
126.40
105.50
88.10
73.40
63.66
56.21
39.49
32.37
% Of Sales
-
5.69%
6.92%
6.03%
4.83%
4.36%
6.43%
7.71%
7.61%
5.98%
6.18%
Selling & Distn. Exp.
-
34.40
98.10
90.00
136.90
143.20
91.60
37.36
26.16
14.82
19.02
% Of Sales
-
1.68%
5.12%
4.30%
6.27%
7.09%
8.03%
4.53%
3.54%
2.24%
3.63%
Miscellaneous Exp.
-
43.20
66.60
58.70
38.50
71.50
24.10
15.31
9.85
7.36
19.02
% Of Sales
-
2.11%
3.48%
2.80%
1.76%
3.54%
2.11%
1.86%
1.33%
1.11%
1.84%
EBITDA
544.90
606.20
582.60
794.80
928.40
683.40
272.60
213.38
179.33
149.93
109.34
EBITDA Margin
28.69%
29.54%
30.42%
37.95%
42.49%
33.83%
23.89%
25.86%
24.27%
22.70%
20.88%
Other Income
101.90
103.60
107.40
130.20
40.40
13.90
9.90
14.91
16.71
12.41
9.14
Interest
11.60
13.30
21.50
19.30
15.40
18.50
22.90
31.68
36.62
26.31
23.04
Depreciation
122.70
116.90
99.80
81.00
66.20
54.40
51.00
47.27
30.44
22.12
15.91
PBT
512.50
579.60
568.70
824.70
887.20
624.40
208.60
149.34
128.98
113.90
79.54
Tax
117.20
137.20
110.60
182.30
192.00
139.50
52.80
3.95
30.87
36.44
21.07
Tax Rate
22.87%
23.67%
19.45%
22.11%
21.64%
22.34%
25.31%
2.94%
23.93%
35.61%
26.49%
PAT
395.30
440.90
460.80
644.40
696.20
486.00
157.10
134.62
102.74
71.87
59.61
PAT before Minority Interest
393.10
442.40
458.10
642.40
695.20
484.90
155.80
130.27
98.11
65.88
58.47
Minority Interest
-2.20
-1.50
2.70
2.00
1.00
1.10
1.30
4.35
4.63
5.99
1.14
PAT Margin
20.82%
21.49%
24.06%
30.77%
31.87%
24.06%
13.77%
16.31%
13.90%
10.88%
11.38%
PAT Growth
-9.63%
-4.32%
-28.49%
-7.44%
43.25%
209.36%
16.70%
31.03%
42.95%
20.57%
 
EPS
21.68
24.19
25.28
35.35
38.19
26.66
8.62
7.38
5.64
3.94
3.27

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
4,121.60
3,773.50
3,489.00
3,072.20
1,649.30
1,295.70
846.05
725.88
533.54
473.63
Share Capital
36.50
36.40
36.50
36.90
34.90
34.80
33.23
33.07
31.37
31.15
Total Reserves
4,067.60
3,713.60
3,421.70
3,011.40
1,599.00
1,251.20
812.82
692.80
502.17
442.49
Non-Current Liabilities
142.90
117.80
83.40
47.10
37.70
28.00
119.23
150.67
191.46
171.34
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
94.03
92.20
135.62
133.88
Unsecured Loans
0.90
0.90
0.00
0.00
0.00
0.00
2.99
3.28
2.21
0.22
Long Term Provisions
99.60
90.20
71.00
32.40
21.90
12.50
9.50
11.09
8.62
6.59
Current Liabilities
525.60
685.30
728.70
592.00
626.50
493.10
413.74
312.28
344.87
259.35
Trade Payables
146.20
255.40
217.00
269.10
262.70
275.60
125.30
109.79
105.85
92.36
Other Current Liabilities
98.60
95.90
109.80
133.40
127.10
114.20
118.56
102.18
90.21
81.91
Short Term Borrowings
266.70
315.00
386.30
173.20
221.60
98.40
168.54
98.63
147.74
81.64
Short Term Provisions
14.10
19.00
15.60
16.30
15.10
4.90
1.33
1.69
1.07
3.44
Total Liabilities
4,791.90
4,587.80
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
1,080.41
905.20
Net Block
2,023.20
1,584.40
1,227.20
1,018.60
833.00
710.10
709.97
644.74
582.75
319.56
Gross Block
2,702.10
2,148.70
1,694.50
1,407.60
1,158.70
983.30
939.98
819.89
726.97
440.33
Accumulated Depreciation
678.90
564.30
467.30
389.00
325.70
273.20
225.82
171.11
140.57
117.34
Non Current Assets
2,454.60
2,262.20
1,955.90
1,584.40
1,230.30
984.70
901.08
827.57
749.94
612.42
Capital Work in Progress
223.40
518.00
637.60
480.00
336.30
211.80
128.96
123.78
105.84
164.43
Non Current Investment
159.40
83.60
19.90
8.10
0.10
0.10
1.57
1.57
1.54
61.79
Long Term Loans & Adv.
44.30
72.00
62.80
75.40
60.40
62.10
57.03
54.25
57.20
66.22
Other Non Current Assets
4.30
4.20
8.40
2.30
0.50
0.60
3.54
3.24
2.61
0.42
Current Assets
2,337.30
2,325.60
2,347.20
2,130.70
1,087.30
837.00
482.97
368.14
330.48
292.79
Current Investments
144.30
28.70
148.70
68.40
32.10
22.10
0.12
0.32
0.81
0.74
Inventories
798.20
558.00
529.00
438.40
348.90
357.30
220.00
181.12
146.02
110.39
Sundry Debtors
412.90
551.30
506.20
637.50
475.20
261.60
192.43
118.80
129.71
94.69
Cash & Bank
283.50
66.00
279.50
183.70
35.80
45.20
13.36
11.05
10.78
36.63
Other Current Assets
698.40
91.60
107.40
53.20
195.30
150.80
57.06
56.85
43.14
50.34
Short Term Loans & Adv.
603.70
1,030.00
776.40
749.50
169.50
125.40
40.97
52.46
38.85
41.84
Net Current Assets
1,811.70
1,640.30
1,618.50
1,538.70
460.80
343.90
69.23
55.85
-14.39
33.44
Total Assets
4,791.90
4,587.80
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
1,080.42
905.21

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
298.80
417.30
668.80
463.60
345.80
112.20
92.67
144.03
61.19
64.94
PBT
579.60
568.70
824.70
887.20
624.40
208.60
134.22
128.98
102.32
79.54
Adjustment
62.10
54.00
14.30
75.60
100.20
90.50
68.14
65.72
48.87
36.97
Changes in Working Capital
-212.90
-97.60
8.60
-294.60
-253.00
-140.70
-85.96
-16.11
-67.39
-27.97
Cash after chg. in Working capital
428.80
525.10
847.60
668.20
471.60
158.40
116.41
178.58
83.80
88.54
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-130.00
-107.80
-178.80
-204.60
-125.80
-46.20
-23.74
-34.55
-22.61
-23.60
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-103.30
-167.00
-612.20
-1,115.50
-299.40
-175.50
-114.75
-108.92
-107.07
-126.94
Net Fixed Assets
-250.20
-335.80
-436.10
-392.40
-299.40
-303.91
-100.13
-99.70
-102.47
-151.51
Net Investments
-145.90
53.30
-94.80
-54.80
-1.00
37.47
-42.37
-11.33
-2.67
-3.71
Others
292.80
115.50
-81.30
-668.30
1.00
90.94
27.75
2.11
-1.93
28.28
Cash from Financing Activity
-185.70
-250.80
-50.90
650.90
-47.70
154.00
29.07
-35.27
26.31
62.78
Net Cash Inflow / Outflow
9.80
-0.50
5.70
-1.00
-1.30
90.70
6.99
-0.15
-19.57
0.78
Opening Cash & Equivalents
19.80
28.30
21.70
23.50
24.20
-164.10
10.22
9.95
34.64
31.70
Closing Cash & Equivalent
25.80
19.80
28.30
21.70
23.50
-74.20
12.44
10.22
9.95
34.64

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
224.88
206.04
189.49
165.22
93.63
73.91
50.91
219.48
170.06
152.06
ROA
9.43%
10.30%
16.02%
23.05%
23.43%
9.72%
10.10%
8.62%
6.64%
7.25%
ROE
11.27%
12.71%
19.75%
29.70%
33.21%
14.62%
16.57%
15.58%
13.08%
14.16%
ROCE
13.99%
14.82%
23.71%
35.28%
39.21%
18.04%
15.62%
18.02%
16.04%
15.72%
Fixed Asset Turnover
0.86
1.07
1.47
1.72
1.93
1.23
0.95
0.96
1.14
1.30
Receivable days
84.44
93.77
91.36
92.22
65.12
70.27
67.76
60.90
61.30
56.98
Inventory Days
118.77
96.38
77.28
65.25
62.41
89.35
87.33
80.17
70.04
73.13
Payable days
50.75
65.96
72.53
81.42
78.30
85.42
73.36
74.09
73.36
79.03
Cash Conversion Cycle
152.46
124.19
96.11
76.05
49.23
74.21
81.73
66.99
57.98
51.07
Total Debt/Equity
0.07
0.08
0.11
0.06
0.14
0.09
0.37
0.33
0.63
0.55
Interest Cover
44.58
27.45
43.73
58.61
34.75
10.11
5.24
4.52
4.89
4.45

News Update:


  • Natco Pharma’s marketing partner launches 10mg strength for Everolimus Tablets in US market
    1st Oct 2021, 11:02 AM

    The U.S. Food and Drug Administration previously granted final approval of this Abbreviated New Drug App

    Read More
  • Natco Pharma’s arm launches NAT-LENALIDOMIDE Capsules
    2nd Sep 2021, 09:47 AM

    NAT-LENADLIDOMIDE is used in combination with dexamethasone for the treatment of multiple myeloma in patients who are not eligible for stem cell transplant

    Read More
  • Natco Pharma transfers Lenalidomide ANDA to Arrow International
    4th Aug 2021, 11:40 AM

    This transfer of the ANDA to Arrow does not materially change any of the terms of the agreement between the parties

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.